Safety and Efficacy of Azilsartan Medoxomil in Participants With Mild to Moderate Hypertension

PHASE2CompletedINTERVENTIONAL
Enrollment

449

Participants

Timeline

Start Date

May 31, 2006

Primary Completion Date

December 31, 2006

Study Completion Date

December 31, 2006

Conditions
Hypertension
Interventions
DRUG

Azilsartan Medoxomil

Azilsartan medoxomil 5 mg and comparator matching placebo tablets, orally, once daily for up to 8 weeks.

DRUG

Azilsartan Medoxomil

Azilsartan medoxomil 10 mg and comparator matching placebo tablets, orally, once daily for up to 8 weeks.

DRUG

Azilsartan Medoxomil

Azilsartan medoxomil 20 mg and comparator matching placebo tablets, orally, once daily for up to 8 weeks.

DRUG

Azilsartan Medoxomil

Azilsartan medoxomil 40 mg and comparator matching placebo tablets, orally, once daily for up to 8 weeks.

DRUG

Azilsartan Medoxomil

Azilsartan medoxomil 80 mg and comparator matching placebo tablets, orally, once daily for up to 8 weeks.

DRUG

Olmesartan

Olmesartan 20 mg and comparator matching placebo tablets, orally, once daily for up to 8 weeks.

DRUG

Placebo

Matching placebo tablets, orally, once daily for up to 8 weeks.

Trial Locations (54)

Unknown

Huntsville

Ozark

Mesa

Little Rock

Carmichael

Long Beach

San Diego

Tustin

Denver

Stamford

Trumbull

Waterbury

Hollywood

Jacksonville

Melbourne

Miami

Pembroke Pines

Pinellas Park

Atlanta

Evansville

Shawnee Mission

Auburn

Trenton

Binghamtom

Rochester

Burlington

Charlotte

Concord

Hickory

Salisbury

Winston-Salem

Cincinnati

Columbus

Oklahoma City

Anderson

Mt. Pleasant

Simpsonville

Bristol

Austin

Dallas

Euless

North Richland Hills

San Antonio

Lakewood

Renton

Madison

BA

Córdoba

Ushuaia

Guadalajara, Jal

Mexico City

Monterrey Nuevo Leon

Morelia, Michoacan

Lima

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Takeda

INDUSTRY